Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.

The article presents questions and answers related to Canada's cancer drug funding decisions including body reviewing drugs, how its is possible for pan-Canadian Oncology Drug Review (pcodr) to recommend not paying for a drug and how do factors enter into the pcodr process.